Spectral Medical (DE:SD4)

FRANKFURT:SD4

SD4

Spectral Medical

RESEARCH TOOLSreports

Spectral Medical (SD4) Price & Analysis

1 Followers

SD4 Stock Chart & Stats

€0.84

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.84

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.48 - €1.11

Previous CloseN/A

Volume0.00

Average Volume (3M)1.32K

Market Cap

€253.44M

Enterprise Value€437.01M

Total Cash (Recent Filing)€1.92M

Total Debt (Recent Filing)€22.27M

Price to Earnings (P/E)―

Beta0.13

Next Earnings

Aug 07, 2026

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding293,418,980

10 Day Avg. Volume3,956

30 Day Avg. Volume1,318

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)-5.93

Price to Sales (P/S)169.36

P/FCF Ratio-42.55

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€2.18

Price Target Upside159.20% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-0.02

Revenue Forecast (FY)€1.66M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthConsistent TTM revenue growth (13.1%) indicates improving market adoption of the PMX therapy and related diagnostics. Sustained top-line momentum provides a path to scale, helps absorb fixed costs, and is a durable lever for improving cash generation if margins and commercialization execute over the next several quarters.

Focused Product & Market NicheA focused therapy-plus-diagnostic strategy targeting endotoxin in sepsis creates a differentiated clinical value proposition. Combining targeted diagnostics with a therapeutic device can improve patient selection, support better clinical outcomes and payer acceptance, and establish a defensible niche in critical care over the medium term.

Lean Operating BaseA small headcount signals a lean cost structure and operational agility, limiting fixed overhead as the company scales commercial and clinical efforts. This structural lightness can extend runway per dollar raised and enable focused investment in high-impact areas like pivotal trials and targeted commercialization.

Bears Say

Highly Stressed Balance SheetThe large equity deficit and minimal asset base limit financial flexibility and increase refinancing and dilution risk. With debt materially exceeding assets, the company is structurally dependent on external capital to operate, which constrains strategic optionality and heightens execution risk over the coming quarters.

Sustained Cash BurnPersistent negative operating and free cash flow of about $11.1M TTM consumes liquidity and forces reliance on financing. Until margins improve or revenues scale substantially, continued cash burn threatens program funding, commercialization cadence, and increases probability of dilutive capital raises within a medium-term horizon.

Extremely Weak Profitability & MarginsDeeply negative gross and net margins reflect a cost structure that currently overwhelms revenue. Without structural improvements to COGS, pricing, or operating leverage, revenue growth is unlikely to translate into sustainable profitability, leaving the company exposed to prolonged cash consumption and investor dilution.

Spectral Medical News

Spectral Medical Advances PMX Toward FDA Submission After Positive Tigris Results

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical reported its fourth quarter and full-year 2025...

3M ago

Spectral Medical’s Tigris Trial Shows Survival Benefit in Endotoxic Septic Shock

An announcement from Spectral Medical ( ($TSE:EDT) ) is now available. Spectral Medical and Vantive reported that full...

3M ago

Spectral Medical (Edtxf) (EDTXF) Q4 Earnings Cheat Sheet

Spectral Medical (Edtxf) (EDTXF) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street...

3M ago

Spectral Medical Pushes Back PMX-20R FDA Filing to Add 12-Month Mortality Data

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical has delayed the timing of its Premarket...

3M ago

Spectral Medical Reports Positive Trial Results and Revenue Growth

Spectral Medical (Edtxf) ( ($EDTXF) ) has released its Q3 earnings. Here is a breakdown of the information...

7M ago

Spectral Medical Reports Positive Tigris Trial Results and Prepares for FDA Submission

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced positive results from its Phase 3...

7M ago

Spectral Medical Files Base Shelf Prospectus to Raise $100 Million

Spectral Medical ( ($TSE:EDT) ) has issued an announcement. Spectral Medical Inc. has filed a final short form...

8M ago

Spectral Medical’s Study Highlights High-Risk Septic Shock Subgroup, Bolstering PMX Therapy Rationale

Spectral Medical ( ($TSE:EDT) ) has shared an update. Spectral Medical announced the publication of a study in...

9M ago

Spectral Medical Sponsors Unite for Sepsis Symposium, Highlights Personalized Treatment

Spectral Medical ( ($TSE:EDT) ) has shared an announcement. Spectral Medical Inc. announced its sponsorship of the Unite...

9M ago

Spectral Medical Secures US$3 Million Funding to Advance Sepsis Treatment

Spectral Medical ( ($TSE:EDT) ) has provided an update. Spectral Medical Inc. has received a US$3 million Tranche...

10M ago

SD4 FAQ

What was Spectral Medical’s price range in the past 12 months?

Spectral Medical lowest stock price was €0.48 and its highest was €1.11 in the past 12 months.

What is Spectral Medical’s market cap?

Spectral Medical’s market cap is €253.44M.

When is Spectral Medical’s upcoming earnings report date?

Spectral Medical’s upcoming earnings report date is Aug 07, 2026 which is in 59 days.

How were Spectral Medical’s earnings last quarter?

Spectral Medical released its earnings results on May 08, 2026. The company reported -€0.006 earnings per share for the quarter, the consensus estimate of -€0.006 by €0.

Is Spectral Medical overvalued?

According to Wall Street analysts Spectral Medical’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Spectral Medical pay dividends?

Spectral Medical does not currently pay dividends.

What is Spectral Medical’s EPS estimate?

Spectral Medical’s EPS estimate is >-0.01.

How many shares outstanding does Spectral Medical have?

Spectral Medical has 293,418,980 shares outstanding.

What happened to Spectral Medical’s price movement after its last earnings report?

Spectral Medical reported an EPS of -€0.006 in its last earnings report, expectations of -€0.006. Following the earnings report the stock price went up 0.585%.

Which hedge fund is a major shareholder of Spectral Medical?

Currently, no hedge funds are holding shares in DE:SD4

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spectral Medical

Spectral Medical Inc., together with its associated companies, specializes in the invention and commercialization of therapeutic solutions for septic shock and kidney disease across North America. The firm offers the Endotoxin Activity Assay, a swift in-vitro diagnostic tool designed to detect elements of gram-negative bacterial cell walls. It also provides Polymyxin B Hemoperfusion, a therapeutic device engineered to cleanse endotoxins from the bloodstream. In addition, Spectral Medical produces and develops monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators. These are employed in both its internal research and development efforts and by other diagnostic enterprises. The company is also advancing a proprietary system for renal replacement therapy. Established in 1991, the organization was initially named Spectral Diagnostics Inc. before transitioning to Spectral Medical Inc. in December 2014. Its main offices are situated in Toronto, Canada.

Spectral Medical (SD4) Earnings & Revenues

Historic Earnings Reports

SD4 Stock 12 Month Forecast

Average Price Target

€2.18

▲(159.20% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","2":"€2","3":"€3","-1":"-€1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":2.177284445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€2.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.177284445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€2.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.177284445,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.18</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0,1,2,3],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,0.9705603419230769,1.0711206838461538,1.1716810257692307,1.2722413676923077,1.3728017096153846,1.4733620515384616,1.5739223934615385,1.6744827353846155,1.7750430773076924,1.8756034192307691,1.9761637611538463,2.076724103076923,{"y":2.177284445,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,0.9705603419230769,1.0711206838461538,1.1716810257692307,1.2722413676923077,1.3728017096153846,1.4733620515384616,1.5739223934615385,1.6744827353846155,1.7750430773076924,1.8756034192307691,1.9761637611538463,2.076724103076923,{"y":2.177284445,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.87,0.9705603419230769,1.0711206838461538,1.1716810257692307,1.2722413676923077,1.3728017096153846,1.4733620515384616,1.5739223934615385,1.6744827353846155,1.7750430773076924,1.8756034192307691,1.9761637611538463,2.076724103076923,{"y":2.177284445,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.52,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.498,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.51,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.915,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.885,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.925,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.805,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.795,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.8,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.845,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.815,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.87,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >